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Abstract: Preclinical studies and adjuvant trials using bisphosphonates have found them to have 
an antitumor effect. Although major advances have been made in chemoprevention strategies 
with selective estrogen receptor modulators and aromatase inhibitors, their use has been fraught 
with significant adverse effects such as venous thromboembolic events and an increased risk 
for endometrial cancer. In this context, several recent observational studies have investigated a 
chemoprevention role for oral bisphosphonates in decreasing risk for breast cancer. This review 
will aim to summarize these studies and present a critical evaluation of the association between 
oral bisphosphonate use and breast cancer risk reduction.
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Introduction
Breast cancer is the most common cancer diagnosis in women. It is estimated that there 
will be more than 220,000 new cases of breast cancer in 2012.1 It is also expected to be 
the leading cause of cancer death in women, with nearly 40,000 deaths predicted this 
year.1 There have been many advances in chemoprevention strategies targeting women 
with high risk for breast cancer involving two categories of drugs – selective estrogen 
receptor modulators (tamoxifen and raloxifene) and aromatase inhibitors.
Current chemoprevention strategies
Numerous randomized controlled trials have established the role of tamoxifen, a 
selective estrogen receptor modulator, in breast cancer prevention.2–4 It was found 
that the use of tamoxifen for 5 years decreased the risk of invasive breast cancer by 
about 50% when compared to placebo.3 However, the significant adverse effects for 
thromboembolic events and the increased risk for endometrial cancer in those treated 
with tamoxifen led to further trials with another selective estrogen receptor  modulator, 
raloxifene.2–5 A trial of raloxifene found a 38% risk reduction for invasive breast cancer 
with the drug when compared to placebo.6 There were also significantly fewer adverse 
effects such as thromboembolic events, uterine hyperplasia, and endometrial cancer 
with raloxifene when compared to tamoxifen.6,7 Both these drugs were approved for 
breast cancer risk reduction by the US Food and Drug Administration. However, in 
clinical practice, both drugs are rarely used for the prevention of invasive breast cancer 
mainly due to persisting concerns about adverse effects.8
The second category of drugs that has been studied in breast cancer chemopreven-
tion is aromatase inhibitors. Several adjuvant trials with aromatase inhibitors found 
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a significant risk reduction for contralateral breast cancers 
compared to tamoxifen use. Furthermore, the MAP.3 breast 
cancer prevention trial in postmenopausal women comparing 
exemestane with placebo found a moderately decreased risk 
for breast cancer with the drug use.9 After a median follow-up 
of about 3 years, the MAP.3 trial found a 65% risk reduc-
tion in the annual incidence of invasive breast cancer when 
compared to placebo. Most notably, there were no signifi-
cant differences between the two groups in the incidence of 
skeletal fractures, cardiovascular events, or cancers. Another 
aromatase inhibitor, anastrozole, is currently being studied for 
breast cancer prevention in postmenopausal women (IBIS-II 
trial).10 It should however, be noted that selective estrogen 
receptor modulators are still the drug of choice for breast 
cancer prevention in premenopausal women.
Bisphosphonates as chemoprevention 
agents in breast cancer
Bisphosphonates are another category of drugs that have been 
explored in the context of the chemoprevention of breast  cancer. 
This review will focus on the role of oral  bisphosphonate 
therapy in decreasing the risk of breast cancer.
Mechanism of action
Bisphosphonates are analogues of pyrophosphate that 
strongly bind to the hydroxyapatite crystals of bone.11 
Osteoclasts induce changes in pH in the bone surface during 
the bone resorptive process, which result in the release of 
bisphosphonates from the bone surface. The bisphosphonates 
are then internalized by osteoclasts through endocytosis. In 
return, the bisphosphonates produce cellular level changes 
leading to an inhibitory effect on the osteoclasts.12 There 
are essentially two kinds of bisphosphonates – non-nitrogen 
containing bisphosphonates such as clodronate and etidronate 
and the nitrogen-containing bisphosphonates (aminobispho-
sphonates) such as alendronate, risedronate, pamidronate, 
and zoledronate (Table 1). The mechanisms of action of 
both these categories of bisphosphonates and their potency 
in inhibiting osteoclasts are quite different. The non-nitrogen 
containing bisphosphonates, after uptake by the osteoclasts, 
are metabolized to hydrolysis-resistant analogs of adenosine 
triphosphate, resulting in apoptosis of the cells and thereby 
inhibiting osteolysis. The nitrogen-containing bisphospho-
nates inhibit the mevalonate pathway in cholesterol synthesis 
by inhibiting farnesyl diphosphate synthase. This property 
of aminobisphosphonates results in the inhibition of post-
translational lipid modification (prenylation) of certain sig-
naling proteins that are essential for cell growth signaling. 
Table 1 Types of bisphosphonates
Types Non-nitrogenous  
bisphosphonates
Nitrogenous  
bisphosphonates
Mechanism of  
action
After uptake into  
osteoclasts, the  
drug metabolizes to  
hydrolysis-resistant  
analogs of ATP and  
leads to apoptosis
After uptake into 
osteoclasts, the drug 
inhibits mevalonate 
pathway in cholesterol 
synthesis (important for 
cell growth signaling) 
thereby resulting in 
apoptosis
Examples Clodronate, Etidronate Alendronate, risedronate, 
pamidronate, zoledronate
Administration Clodronate – po and iv 
(not available in US)
Etidronate – po
Alendronate – po
Risedronate – po
Pamidronate and 
zoledronate – iv
Abbreviations: ATP, adenosine triphosphate; po, by mouth; iv, intravenous.
Table 2 Indications for bisphosphonate use
Treatment of osteoporosis
Treatment of hypercalcemia
Prevention of skeletal-related events in bone metastasis
Prevention of chemotherapy-induced bone loss
Ultimately, the mevalonate pathway inhibition results in the 
induction of osteoclast apoptosis.12
Antitumor role
Bisphosphonates are currently indicated for the treatment of 
osteoporosis and hypercalcemia, the prevention of skeletal-
related events in bone metastasis, and in the prevention of 
chemotherapy-induced bone loss (Table 2). However, several 
preclinical models and clinical studies have observed an 
antitumor effect with bisphosphonate use. Numerous in vitro 
models have found that bisphosphonates exhibit an antitumor 
effect by inducing apoptosis, decreasing cell proliferation, 
and by inhibiting tumor cell migration and angiogenesis 
(Table 3).13–18
These preclinical data led to several clinical trials of the adju-
vant use of bisphosphonates in breast cancer.19–25 For instance, 
a study of adjuvant zoledronate use in around 3300 patients 
with early breast cancer found no significant survival 
 benefit.20 However, a subgroup analysis based on menopausal 
 status found evidence of significant heterogeneity, favoring 
 adjuvant zoledronate use in improving overall survival in 
postmenopausal women.20 Another study of zoledronate, used 
upfront versus in a delayed manner, in 602  postmenopausal 
women with early breast cancer on an aromatase inhibitor 
found no difference in recurrence rates at 61 months of 
follow-up (P = 0.62).22 However, a study of zoledronate in 
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1800 premenopausal women with early breast cancer found 
a significant risk reduction of 39% in the zoledronate group 
as compared to placebo (adjusted hazard ratio: 0.61; 95% 
confidence interval [CI]: 0.39–0.96; P = 0.033).21 In addition, 
several adjuvant trials with bisphosphonates in early breast 
cancer are currently progressing.
Observational studies of bisphosphonates  
in reducing the risk of breast cancer
As a result of the observations from the above preclinical and 
clinical studies, investigators have tried to evaluate the role 
of bisphosphonates in the chemoprevention of breast cancer. 
Four observational studies exploring this association were 
identified on a review of the literature and are summarized 
in Table 4.
Newcomb et al conducted a case-control study which 
looked at the incidence of breast cancer in women who 
used bisphosphonates for the treatment of osteoporosis.26 
Around 3000 incident cases of breast cancer and a control 
group were identified in the state of Wisconsin in the USA. 
Bisphosphonate use, known risk factors for breast cancer, 
and other potential confounding variables were ascertained 
by interview. Of note, more than 97% of the study popula-
tion used aminobisphosphonates. In multivariable logistic 
regression analysis, the odds ratio for breast cancer in cur-
rent bisphosphonate users compared with nonusers was 0.67 
(95% CI: 0.51–0.89). The authors also noted a statistically 
significant inverse dose–response relationship between breast 
cancer risk and the increasing use of oral bisphosphonates 
(P = 0.01). It should be noted that recall bias and unmeasured 
confounding with factors such as bone mineral density and 
alcohol use could have played a major role in biasing the 
results of this case-control study.
The second study by Rennert et al retrospectively looked 
into the relationship between bisphosphonate use and risk 
reduction of breast cancer.27 In this case-control study, 1832 
patients with postmenopausal breast cancer were identified 
from the northern part of Israel. The investigators used an 
insurance database to obtain 2207 controls that were age-, 
clinic-, and ethnicity-matched. Data on bisphosphonate use 
were obtained from pharmacy records and were classified 
into categories based on the number of years used. Of note, 
more than 85% of the study population used alendronate, 
an oral preparation. In a multivariable analysis adjusting 
for significant risk factors and confounding factors such 
as age, fruit and vegetable consumption, family history, 
body mass index, hormone replacement therapy, number 
of pregnancies, months of breast-feeding, and age at first 
pregnancy, the investigators found a significant reduction 
in breast cancer risk of 28% (hazard ratio: 0.72; 95% CI: 
0.57–0.90) with bisphosphonate use for more than 1 year 
before the diagnosis of cancer. Similar results were also 
found for bisphosphonate use regardless of duration (odds 
ratio: 0.80; 95% CI: 0.65–0.99). However, the authors did 
a subgroup analysis in study participants who used bispho-
sphonate for less than 1 year before diagnosis and found no 
significant risk reduction in breast cancer (odds ratio: 0.93; 
95% CI: 0.61–1.42).
Furthermore, note that the sample size for this analysis 
was only 43 patients and 46 controls. Again, similar to the 
previous case-control study, the Israeli study was also unable 
to adjust for an important confounding variable: bone min-
eral density. It is known that low bone mineral density or 
osteoporosis is associated with a decrease in breast cancer 
risk.28,29 Conversely, postmenopausal women with greater 
bone mineral density have been found to have a higher risk 
for breast cancer.30 In addition, low bone mineral density is 
also an indication for bisphosphonate use. Hence, the con-
clusion of the previous studies could be confounded by the 
potentially low bone mineral density of people in the control 
group (Figure 1).
Most of the data in the above two studies could be biased 
by recall, a problem inherent in the design of case-control 
studies. One option to circumvent this limitation would be 
to design a nested case-control study in larger prospective 
cohorts with baseline measurements of potential confound-
ing factors. Unfortunately, for diseases such as cancer, 
assembling huge cohorts to successfully conduct a nested 
case-control study would be a challenging situation with 
considerable cost implications.
The recently published Women’s Health  Initiative 
 substudy aimed to tackle this question in a nested 
case-control study design.31 In this study, Chlebowski 
et al attempted to investigate the association between 
oral  bisphosphonate use and breast cancer incidence 
in  postmenopausal women. The WHI cohort offered a 
 particular advantage for investigating this association in 
that it had a baseline bone mineral density measure in about 
10,000 of the 150,000 study population.
Table 3 Possible mechanisms for the antitumor effects of 
bisphosphonates
Inhibit cancer cell adhesion to extracellular matrix proteins
Inhibit cancer cell proliferation and induce apoptosis
Inhibit cancer cell migration and invasion
Inhibit angiogenesis
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In an earlier study, from within the population that had 
a baseline measurement of bone mineral density, it was 
found that high bone mineral density was associated with an 
increased risk for breast cancer, independent of Gail breast 
cancer risk score.29 Another study from the entire WHI cohort 
also found a predictive model of 5-year risk for hip fracture.32 
However, this risk prediction model did not include bone 
mineral density as one of the variables. The authors were then 
able to investigate the correlation of 5-year hip fracture risk 
score and bone mineral density in about 10,000 people who 
had both of these variables measured at baseline. Based on 
their analysis, the authors found that the 5-year hip fracture 
risk score correlated well with hip bone mineral density.31 
Therefore, the authors were able to use the risk score as a 
surrogate for bone mineral density in the multivariate Cox 
proportional hazards analysis.
Table 4 Observational studies on oral bisphosphonate use in decreasing breast cancer risk
Study and location Population Conclusions Comments
Newcomb et al26
USA
2936 breast cancer patients and  
2975 population controls
OR:a 0.67 (95% CI:  
0.51–0.89)
•  Case-control study design.
•  Interview-based, hence, more risk for recall bias.
•   Significant dose–response relationship was identified 
with increasing use of the drug (P-trend = 0.01).
•  Unable to adjust for low BMD.
Rennert et al27
Israel
1832 patients with postmenopausal  
breast cancer and 2207 age-, clinic-,  
ethnicity-matched controls
OR:b 0.80 (95% CI:  
0.65–0.99)
•  Case-control study design
•  Drug use was assessed from pharmacy database, hence, 
more reliable. However, other variables are still prone 
for recall bias.
•  Drug use for less than 1 year had no association with 
breast cancer incidence.
•  Compliance with daily use was 72% and with weekly use 
was 88%.
•  Unable to adjust for low BMD.
Chlebowski et al31
USA
154,768 participants of the Women’s  
Health Initiative cohort
HR:c 0.68 (95% CI:  
0.52–0.88)
•  Nested case-control design within a cohort of 
postmenopausal women.
•  Data were prospectively collected. Hence, recall bias 
is minimized. However, drug use was ascertained by 
questionnaire methods.
•  Nearly 5156 women were diagnosed with breast cancer 
of whom 1120 were diagnosed with DCIS.
•  Used a surrogate marker for BMD – 5-year hip fracture 
risk score. There still might have been some significant 
residual confounding with low BMD.
•  Study found an increased risk for DCIS in drug users.
Cardwell et al33
UK
41,826 bisphosphonate users and  
41,826 age-, sex- and practice- 
matched controls
HR:d 0.75; (95% CI:  
0.63–0.89)
•  Nested case-control design within the General Practice 
Research Database that includes nearly 6% of the UK 
population.
•  Most of the data were prospectively collected. However, 
drug use was ascertained from prescriptions.
•  Cancers were ascertained from diagnostic codes in 
patient files and not from cancer registries.
•  Other exposure variables such as smoking status, BMI, 
and alcohol use were ascertained from diagnostic codes 
and chart review – all subject to inaccuracies.
•  An exploratory analysis was conducted to adjust for 
confounding with low BMD. However, sample size for 
the analysis is small, at 25 in each group. Therefore, 
residual confounding might have influenced the results.
Notes: aAdjusted for age at first birth,  family history of breast cancer, body mass index, menopausal status, age at menopause, diagnosis of osteoporosis, smoking, and 
number of mammograms; banalysis was done for any bisphosphonate use. Similar results were obtained when analysis was done for bisphosphonate use .1 year. However, 
no statistically  significant  association was observed  in patients with ,1 year of bisphosphonate use. Adjusted for age, fruit and vegetable consumption, sports activity, 
family history of breast cancer, ethnicity, body mass index, use of calcium, hormone replacement therapy, number of pregnancies, months of breast-feeding, and age at first 
pregnancy; cadjusted for age, ethnicity, smoking, alcohol use, physical activity, body mass index, mammogram in last 2 years, prior hormone replacement therapy or oral 
contraceptive use, calcium and vitamin D levels, 5-year hip fracture risk score, and Gail breast cancer risk score; dadjusted for potential risk and confounding factors such as 
body mass index, smoking, alcohol use, and nonsteroidal anti-inflammatory drug or steroid use of calcium and vitamin D, and hormone replacement therapy use.
Abbreviations: OR, odds ratio; CI, confidence interval; BMD, bone mineral density; HR, hazard ratio; DCIS, ductal carcinoma in situ; BMI, body mass index.
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The final sample size included 154,768 participants, 
excluding both women with a prior diagnosis of breast cancer 
as well as those with a history of tamoxifen or raloxifene 
use. Bisphosphonate use was ascertained by questionnaire 
at baseline and at year 3 in all participants, and additionally 
at year 1 in a subset of participants. It was found that around 
2800 people used oral bisphosphonates at baseline. These 
participants had a significantly higher risk for hip fracture at 
5 years based on the risk score model. It was also found that 
5156 women were diagnosed with breast cancer and 1120 
women were diagnosed with ductal carcinoma in situ (DCIS) 
after around 1.2 million person-years of observation.
The multivariate Cox proportional hazards model 
adjusted for age, ethnicity, smoking, alcohol use, physical 
activity, body mass index, mammogram in the last 2 years, 
prior hormone replacement therapy or oral contraceptive use, 
calcium and vitamin D levels, 5-year hip fracture risk score, 
and Gail breast cancer risk score. It was observed that oral 
bisphosphonate users had a 32% reduction in risk for breast 
cancer (hazard ratio: 0.68; 95% CI: 0.52–0.88; P , 0.01) 
after adjusting for the possible risk factors and confounding 
variables noted above. It was also noted that the risk for DCIS 
was increased in bisphosphonate users (hazard ratio: 1.58; 
95% CI: 1.08–2.31; P = 0.02).
Although this study found a significant protective role 
for oral bisphosphonate use in reducing the risk for breast 
cancer, it raised several questions. Does the 5-year hip 
fracture risk score adequately account for the confounding 
with bone mineral density? Are the findings affected by any 
residual confounding factors? What about the increased risk 
for DCIS in bisphosphonate users? Note that the increased 
incidence of DCIS with increasing drug exposure mirrored 
a pattern also observed with raloxifene use in the Breast 
Cancer Prevention Trial.6
The fourth study investigating the association between 
oral bisphosphonate use and breast cancer incidence was 
from the General Practice Research Database in the United 
Kingdom,33 which is one of the largest databases of anony-
mized longitudinal patient records and includes nearly 6% 
of the UK population. The authors put together a cohort of 
bisphosphonate users (n = 41,826) and an age-, sex-, and 
practice-matched control population in a 1:1 matched ratio. 
This nested case-control study excluded participants if they 
had a prior history of cancer or if they had less than 6 months 
of follow-up.
In a Cox proportional hazard analysis, adjusting for poten-
tial risk and confounding factors such as body mass index, 
smoking, alcohol use, and nonsteroidal anti-inflammatory 
drug, steroid, use of calcium and vitamin D supplements, and 
hormone replacement therapy use, the study found a signifi-
cant risk reduction of 25% in any users of bisphosphonates 
as compared to their matched controls (adjusted hazard ratio: 
0.75; 95% CI: 0.63–0.89; P , 0.001). Subgroup analysis in 
women who used bisphosphonates for at least 1 year yielded 
a similar risk reduction for breast cancer, although this was 
not statistically significant (adjusted hazard ratio: 0.79; 95% 
CI: 0.62–1.01; P = 0.06). Further testing of a dose–response 
relationship in study participants who used bisphosphonates 
for at least 3 or 4 years found no evidence of an association.
Furthermore, in an attempt to explore confounding by 
low bone mineral density on breast cancer risk, the authors 
conducted an analysis using participants from the control 
population who had a diagnosis of osteoporosis or fracture 
and their matched bisphosphonate users. It was observed that 
there was no association between bisphosphonate use and 
breast cancer risk reduction, although the sample size was 
only around 25 in each group for this analysis.
Conclusions
These results showed a signif icant risk reduction for 
breast cancer with bisphosphonate use, although the pres-
ence of possible unmeasured confounding factors and the 
Low bone mineral density
Bisphosphonate use Decreased incidence of breast cancer
Figure 1 Potential confounding role of low bone mineral density in the relationship between bisphosphonate use and breast cancer incidence.
Notes: Low bone mineral density could result in bisphosphonate use. It is also known that low bone mineral density is associated with a decreased incidence of breast cancer. 
Therefore, the relationship between bisphosphonate use and breast cancer risk could be influenced by confounding with low bone mineral density.
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 observational nature of these studies affected the strength 
of these conclusions. It should, however, be noted that these 
results are backed by the evidence of a biological plausibility 
from in vitro models. As noted from the preclinical models 
and clinical studies in breast cancer patients, bisphosphonates 
are purported to influence the tumor microenvironment in 
decreasing breast cancer growth and spread. Therefore, these 
observational studies may simply extend the benefit early 
into the continuum of breast cancer progression.
In conclusion, although these observational studies 
showed a roughly 20%–30% risk reduction for breast cancer 
with bisphosphonate use, it could only be considered hypoth-
esis generating rather than practice changing. As described 
above, several confounding factors could have influenced 
these findings, most notably, that of low bone mineral density. 
Only a prospective cohort study with a baseline measure-
ment of bone mineral density would adequately address this 
significant confounding factor in the relationship between 
bisphosphonate use and breast cancer incidence. In addi-
tion, the ideal study in this context would be a randomized 
controlled trial, adjusting for bone mineral density, smoking 
status, body mass index, alcohol use, hormone replacement 
therapy use, and other risk factors for breast cancer.  Needless 
to say, given the increasing number of postmenopausal 
women who are placed on bisphosphonates for osteoporosis 
and bone protection, the association between oral bisphos-
phonate use and breast cancer incidence has significant public 
health implications and needs to be explored further.
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